Chairperson RLS EBM task force.
Version of Record online: 16 OCT 2008
Copyright © 2008 Movement Disorder Society
Volume 23, Issue 16, pages 2267–2302, 15 December 2008
How to Cite
Trenkwalder, C., Hening, W. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., Costa, J., Stiasny-Kolster, K. and Sampaio, C. (2008), Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov. Disord., 23: 2267–2302. doi: 10.1002/mds.22254
Produced by a task force commissioned by The Movement Disorder Society.
Potential conflicts of interest: Claudia Trenkwalder, MD, has been an advisor for Boehringer Ingelheim, Cephalon, Mundipharm, Orion Pharma and Schwarz Pharma. She has received consultant honoraria from GlaxoSmithKline, Boehringer Ingelheim GmbH, UCB/Schwarz Pharma, and Novartis; Wayne A. Hening, MD, PhD, has received grant support from GlaxoSmithKline, and consultancy and speaking honoraria from Boehringer Ingelheim, and consultancy honoraria from Schwarz-Pharma; Pasquale Montagna, MD, has received research funding from GlaxoSmithKline and Schwarz Pharma, and has received consultant honoraria from Boehringer Ingelheim GmbH; Wolfgang H. Oertel, MD, has been an advisor for Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, and Schwarz Pharma and has received consultant honoraria from Boehringer Ingelheim, Hoffmann LaRoche, and Schwarz Pharma; Richard P. Allen, PhD, has received consultant honoraria from GlaxoSmithKline, Boehringer Ingelheim, UCB, Xenoport, Sepracor, Norvatis, Orion Pharma. Respironics, IM systems. Pfizer, Jazz, Schwarz Pharama, and Neurogen. He has received grant support from the NIH, GlaxoSmithKline and Sepracor; Arthur S. Walters, MD, has been an advisor for GlaxoSmithKline, Boehringer Ingelheim, Xenoport, UCB/Schwarz Pharma, and Orion/Novartis. He has received research funding from GlaxoSmithKline, Boehringer Ingelheim, Xenoport, UCB/Schwarz Pharma and Kyowa; Karin Stiasny-Kolster, MD, has been an advisor for Boehringer Ingelheim, Orion, Mundipharma, Pfizer, Schwarz Pharma, Synosia and UCB and has received consultant honoraria from Schwarz Pharma, UCB, and Boehringer Ingelheim; Cristina Sampaio, MD, PhD and Joao Costa's, MD, department has received grants from or payments from the following companies: Kyowa, Schering-Plough, Lundbeck, UCB, Neurobiotech, Solvay, Servier, Xytis, Gruenthal, Eisai, Novartis, Fujisawa/Astellas, Neuron/Serono, Bial, GlaxoSmithKline and Novartis. In no circumstances were these grants/payments related to a development program concerning RLS.
- Issue online: 21 DEC 2008
- Version of Record online: 16 OCT 2008
- Manuscript Accepted: 6 JUL 2008
- Manuscript Revised: 20 JUN 2008
- Manuscript Received: 21 JAN 2008
- Boehringer Ingelheim GmbH
- Hoffmann-LaRoche Ltd.
- Orion Pharma
- Schwarz Pharma AG
- 1Treatment of restless legs syndrome and periodic leg movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 12: 1845–1848., , , .
- 54Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a world association of sleep medicine—international restless legs syndrome study group consensus conference at the Max Planck Institute. Sleep Med 2007; 8: 520–530., , , et al.
- 55Astenia crurum paraesthetica (“Irritable legs”). Acta Med Scand 1944; 148: 197–209..
- 56Evidence-based medicine: how to practice and teach EBM. 2nd ed. London, UK: Churchill Livingstone; 2000., , , , .
- 60Synthesis of best evidence for clinical decisions. In: MulrowCD,CookDJ, editors. Systematic reviews, synthesis of best evidence for health care decisions. Philadelphia: American College of Physicians; 1998. p. 5–12., , .
- 64Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990; 43: 891–905., , , , .
- 66Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill Professional; 2001., , , .
- 90A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med (in press)., , , , , .